<div id="readability-page-1">The cross-border outlicensing activities of Chinese biotech firms reached a record transaction value of US$60 billion in the first quarter of 2026, driven by multinational pharmaceutical companies’ growing appetite for the country’s promising drug candidates. The deal value represented a 73 per cent jump from the same period a year earlier, and accounted for nearly half of the total US$135.7 billion worth of agreements signed throughout 2025, the National Medical Products Administration (NMPA) said in a statement on Saturday. The drug regulator did not reveal the number of transactions. Outlicensing agreements typically involve a company granting another firm the exclusive rights to further develop, manufacture and commercialise a drug once it has entered human clinical trials, in return for upfront payments, milestone fees and royalties on future sales. “Chinese biotech firms have shown substantial technological advancements over the past few years and some of their innovative research has piqued the interest of international pharmaceutical big names,” said Meng Tianying, a senior executive at Shanghai-based consultancy Domo Medical. “It has become a new bright spot of the Chinese economy in line with the government’s efforts to encourage innovation.” Innovative drugs – novel medicines targeting unmet medical needs, including new chemical entities and advanced biologics – were expected to grow at an annualised pace of 20 per cent between 2026 and 2030 in mainland China, before slowing to 8.8 per cent from 2030 to 2040, according to Chen Chen, head of China healthcare research at UBS.  The Swiss bank estimated last year that the mainland’s pharmaceutical industry would rise by 50 per cent between 2024 and 2030, generating revenues of US$2.1 trillion by 2030. An ageing population offered the biggest boost to drug and medical device businesses in China, with the market size likely to top US$3.2 trillion in 2050, Chen said in a media briefing in October. Among the latest outlicensing deals involving China-originated drugs, Hong Kong-listed Sino Biopharmaceutical agreed with Sanofi early this month to grant the French pharmaceutical company the exclusive worldwide rights to develop, manufacture and sell rovadicitinib, an oral drug to treat blood cancer and immune-related diseases. The deal was worth US$1.53 billion. Also in early March, Antengene Corporation signed a US$1.18 billion pact with Belgium’s UCB, under which the Brussels-listed company obtained an exclusive worldwide licence to manufacture and commercialise ATG-201, an experimental antibody-based therapy treating autoimmune diseases. Other notable outlicensing deals so far this year include a January 29 tie-up in which AstraZeneca agreed to pay US$1.2 billion upfront to China’s CSPC Pharmaceutical in a weight-loss drug collaboration worth up to US$18.5 billion, and an early-February Innovent Biologics-Eli Lilly partnership involving US$350 million upfront and as much as US$8.5 billion in milestones for next-generation cancer and immunology drugs. Innovative efforts by biotech firms have also bolstered Beijing’s ambitions to build China into a technology powerhouse with a grasp of core technologies amid an uncertain geopolitical outlook. A total of 157 cross-border outlicensing deals worth a record US$135.7 billion were signed between Chinese companies and overseas partners in 2025, compared with 94 transactions worth US$51.9 billion in 2024, according to NMPA data. Tony Ren, head of Asia healthcare research at Macquarie Capital, said earlier this year that 2026 would see another 50 to 60 per cent increase in deal value, after more than doubling in 2025.</div>

159102

<p>Chinese biotech firms achieved a record US$60 billion in cross-border outlicensing deals in Q1 2026, a 73% increase from the previous year. This surge reflects multinational pharmaceutical companies' interest in China's innovative drug candidates. Notable deals include Sino Biopharmaceutical's US$1.53 billion agreement with Sanofi and Antengene's US$1.18 billion pact with UCB. The Chinese pharmaceutical market is projected to grow significantly, driven by an aging population and technological advancements in biotech, with revenues expected to reach US$2.1 trillion by 2030.</p>

SCMP

Huaan Hang Seng Biotech ETF

iShares Global Healthcare

VG Health

SPDR S&P Biotech

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Invesco Nasdaq Biotechnology ETF

GX CN BIOTECH

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

GF CSI HK Innovative Drugs Industry ETF(QDII)

Proshares Ultra Nasdaq Biotech

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

iShares Biotechnology ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ANTENGENE-B

ChinaAMC SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

First Trust NYSE Arca Biotech Index Fd

China Southern Hang Seng Biotech ETF(QDII)

ALPS Medical Breakthrough

ChinaAMC SSE Health Care ETF Initiating Fund

Ark Genomic Revolution ETF

China Universal 800 Health Care ETF

SIHUAN PHARM PREF OFFER

iShares US Pharma

SBP GROUP

ICBCCS SSE STAR Biology and Medicine ETF

VanEck Biotech ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai SSE STAR Brand Name Drug ETF

Penghua SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bull 3X

Sanofi

Invesco Biotechnology & Genome ETF

Bosera Hang Seng Health Care ETF(QDII)

SPDR S&P Health

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China biotech deals hit record as innovative drugs draw global interest